BioCryst Drug Galidesivir to start Clinical Trials & New Vaccine Information from Oxford and AstraZeneca

Active Body Nutritions

Active Body Nutritions

Blog posts regularly on health news and important topics

BioCryst Drug Galidesivir to start Clinical Trials & New Vaccine Information from Oxford and AstraZeneca

We’re going to be taking a look at a different experimental drug in regards to Covid-19 treatment.  From the company BioCryst, Galidesivir has been given the green light for clinical trials for treatment of patients with the Corona virus.

Back in early April, the company announced that they opened enrollment to a randomized, double-blind, placebo-controlled clinical trial to check the safety and effectiveness of the antiviral drug Galidesivir.  Another experimental antiviral drug, the success of Galidesivir in relation to covid-19 effectiveness relies on the time to clinical improvement, time to hospital discharge, and time to undetectable levels of the virus. 

The study will take place in Brazil and will test 24 hospitalized adults with mild to severe symptoms of Covid-19 and is being funded by the National Institute of Allergy and Infectious Diseases.  Some hopeful information about the experimental drug is that in animal studies, Galidesivir has demonstrated activity against a variety of serious pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses.

We’ll be keeping watch on all of the news surrounding this, and other experimental drugs and news of their clinical trials with Covid-19.  This study in particular was announced in early April, and while there was no timetable to get results, we can expect to hear something from BioCryst in the coming weeks.

Now we want to turn our attention to a multinational pharmaceutical and biopharmaceutical company, AstraZeneca.  They have announced an agreement with Oxford University to begin work on the global development and distribution of Oxford’s potential vaccine of Covid-19.  The vaccine is being developed by the Jenner Institute and Oxford Vaccine Group at the University of Oxford, and under the agreement, AstraZeneca will be responsible for the development, manufacturing, and distribution of the vaccine.

Officials in the UK government say “This collaboration between Oxford University and AstraZeneca is a vital step that could help rapidly advance the manufacture of a coronavirus vaccine”.  Professor Sir John Bell of Oxford said, “Our partnership with AstraZeneca will be a major force in the struggle against pandemics for many years to come. We believe that together we will be in a strong position to start immunizing against coronavirus once we have an effective approved vaccine”.

As always be sure to check back with us for more up to date information and news regarding experimental drug trials concerning the Coronavirus.